Taken as a whole, these results suggest imaging of DA neurotransmission in PD may have at least, two important clinical applications: Diagnosis in both clinical and preclinical phases. A biomarker for the efficacy of agents designed to slow progression of the disease, ie, neuroprotective agents. Significant controversy surrounds the utility of imaging to provide a “biomarker for efficacy” (ie, a surrogate end point.) for a potential neuroprotective agent. On first consideration, it. seems Inhibitors,research,lifescience,medical obvious

that DA imaging is a useful end point in a clinical study and provides a useful surrogate for clinical efficacy. However, this may not be the case. For example, a false-positive imaging end point could result, from an agent that slows the loss of the target, but has no clinically significant effect for the patient’s symptomatology. Such a result may be the case for a study of SPECT DAT imaging in patients with Inhibitors,research,lifescience,medical pramipexole, where DAT loss was slower in the experimental group, but. with no clinically significant differences between groups.1 One possible interpretation

of these results is that pramipexole has odd effects on DAT levels, but. is not a good measure of overall DA neurotransmission. Even more dramatic examples Inhibitors,research,lifescience,medical of a falsepositive surrogate end point, exist. For example, the antiarrhythmic agents flecainide and encainide were evaluated with electrocardiogram (F.CG) as Inhibitors,research,lifescience,medical their “surrogate end point,” since agents that decrease ECG arrhythmias must certainly help the patient. In fact, these medications decreased arrhythmias, but, after approval by the Federal Drug Administration (FDA), were found to be associated with elevated cardiac mortality.2 This example surely shows the need to validate surrogate end points, lest the treatment is found to cure the disease Inhibitors,research,lifescience,medical and kill the patient! In the summer of 2003, the National Institutes of Neurological Disorders and Stroke organized a panel of experts with various backgrounds (including PD, imaging, and regulatory affairs) to assess the utility of DA imaging

in PD.The consensus of this group was that DA imaging of these three targets provide useful biomarkers to study pathophysiology, but that additional studies heptaminol are needed for them to be accepted by the field and the FDA as validated surrogate end points. Enthusiasm was strong for additional prospective studies to be performed by academic researchers, often in collaboration with industry and with input from regulatory authorities such as the FDA.
Those of us who study the nervous system believe that the brain is the organ that controls our behavior. Therefore, what we think and what we do, while obviously influenced by the experience, are results of the brain’s processing of information and directing our RGFP966 datasheet subsequent actions. Given this basic assumption, it is no wonder that the most common model or analogy of how the brain operates is that of a computer.